Archives
URB597 (KDS-4103): Reliable FAAH Inhibition for Endocannabin
2026-07-09
This article explores how URB597 (SKU A4372) addresses real-world challenges in endocannabinoid signaling, neuroinflammation, and neuroplasticity research. Using scenario-driven Q&A, it demonstrates how APExBIO's URB597 offers reproducible FAAH inhibition with validated workflow parameters, supporting robust cell-based and in vivo assays.
HATU in Peptide Synthesis Chemistry: Protocols & Innovations
2026-07-08
HATU delivers unmatched efficiency and selectivity in amide bond formation, elevating peptide synthesis chemistry for both routine and complex targets. By integrating recent structural and workflow innovations, researchers can now achieve higher yields and rapid couplings with fewer side reactions—essential for modern drug discovery pipelines.
AMG 9810: Potent TRPV1 Antagonist for Pain Mechanism Researc
2026-07-08
AMG 9810 is a nanomolar-potency TRPV1 antagonist widely used in pain and sensory neuron research. It selectively inhibits capsaicin-induced calcium influx and CGRP release, enabling robust in vitro and in vivo studies of TRPV1-mediated pathways. The compound’s solubility and stability profile are well characterized for laboratory workflows.
Sex Differences in Cannabinoid Withdrawal: Insights from WIN
2026-07-07
This study investigates sex-specific somatic and anxiety-like behaviors in rats during withdrawal from the synthetic cannabinoid agonist WIN 55,212-2, using rimonabant (SR141716) to precipitate withdrawal. The findings reveal qualitative differences between males and females in withdrawal symptomatology, advancing mechanistic understanding of endocannabinoid system modulation relevant to addiction and withdrawal research.
Cabozantinib Blocks MLKL to Inhibit Necroptosis and Psoriasi
2026-07-07
The reference study uncovers cabozantinib as a direct inhibitor of necroptosis through selective blockade of MLKL oligomerization, a mechanism distinct from conventional upstream kinase inhibitors. This discovery demonstrates cabozantinib's therapeutic efficacy in a psoriasis mouse model and highlights its drug repurposing potential for necroptosis-driven inflammatory diseases.
Halazone and Oxidant Effects on Sodium Channel Inactivation
2026-07-06
This article examines a pivotal study on how Halazone and related oxidants modulate sodium current inactivation in voltage-clamped myelinated frog nerve fibers. The findings challenge prior assumptions about amino acid residue involvement and suggest membrane lipid modification as a key mechanism, with implications for neurophysiology and antimicrobial sulfonamide research.
MDM1 Overexpression Enhances p53-Mediated Apoptosis in CRC T
2026-07-06
This study reveals that MDM1 overexpression in colorectal cancer (CRC) cells promotes p53 expression and apoptosis, improving sensitivity to chemoradiotherapy. These findings position MDM1 as a promising predictive biomarker for treatment response and suggest new avenues for optimizing therapeutic strategies in CRC.
Rottlerin (SKU B6803): Best Practices for Reliable PKC Inhib
2026-07-05
This article provides an evidence-based guide for optimizing cell viability and apoptosis assays using Rottlerin (SKU B6803), a selective PKC inhibitor from APExBIO. Through five real-world laboratory scenarios, we address challenges in experimental design, protocol optimization, data interpretation, and vendor selection, ensuring that biomedical researchers can achieve reproducible, high-sensitivity results.
Parathyroid hormone (1-34) (human): Precision for Bone & Kid
2026-07-04
Parathyroid hormone (1-34) (human) is transforming advanced bone metabolism and kidney disease research by enabling high-fidelity, receptor-specific assays that recapitulate core in vivo mechanisms. Its validated performance and reproducible effects empower translational workflows that bridge molecular signaling and disease modeling. Leverage APExBIO’s rigorously characterized peptide for unrivaled experimental reliability.
IPR-803 and the Next Frontier in Tumor Microenvironment Modu
2026-07-03
This thought-leadership article unpacks the mechanistic and translational significance of IPR-803, a competitive urokinase receptor inhibitor, within the evolving landscape of tumor microenvironment targeting. By weaving together recent mechanistic insights, validated protocols, and strategic outlooks, the article offers translational researchers a blueprint for leveraging IPR-803 in preclinical and emerging nanomedicine workflows—especially for breast and pancreatic cancer. Beyond summarizing current evidence, the discussion highlights how IPR-803 enables a paradigm shift from mere cytotoxicity to stroma and angiogenesis modulation, referencing recent advances in sequential nanomedicine delivery and offering practical guidance for experimental design.
Translatome Remodeling Links Fasting, Ketogenesis, and Tumor
2026-07-03
Yang et al. (2024) reveal that fasting induces selective remodeling of hepatic mRNA translation through the AMPK-MNK-eIF4E axis, controlling ketogenesis and exposing metabolic vulnerabilities in pancreatic tumors. This study uncovers a direct molecular bridge between diet, translational control, and cancer therapy, with implications for targeting the MNK-eIF4E signaling pathway.
Structural Insights into ASCH Domains and N4-Acetylcytidine
2026-07-02
Meng et al. provide the first detailed structural and mechanistic analysis of ASCH domain-containing proteins, revealing that EcYqfB specifically hydrolyzes free N4-acetylcytidine (ac4C) nucleoside but does not remove ac4C from RNA. This work clarifies substrate specificity among ASCH homologs and advances understanding of nucleotide processing in RNA epigenetics research.
Triamcinolone Protocol Guidance for Glucocorticoid Research
2026-07-02
Triamcinolone (SKU B1859) is a synthetic glucocorticoid agonist designed for in vitro studies of glucocorticoid signaling, inflammation, and immunosuppression. This compound is not suitable for diagnostic or clinical use and demands strict attention to solubility, handling, and storage to ensure data integrity.
BMS-777607: c-Met Inhibitor Enhances Stem Cell Platelet Prot
2026-07-01
BMS-777607, a highly selective c-Met inhibitor, empowers researchers to precisely modulate MET signaling in both cancer and stem cell-derived platelet models. Its integration into hiPSC-to-megakaryocyte workflows accelerates maturation, boosts yield, and offers new cost-effective strategies for scalable platelet production.
Practical Guide: DiI (DiIC18(3)) Plasma Membrane Orange Fluo
2026-07-01
DiI (DiIC18(3)) enables precise, high-contrast plasma membrane labeling in both live and fixed biological systems. It is ideal for neuronal tracing and cell migration workflows but should be avoided in aqueous protocols or for non-membrane organelle labeling. Proper preparation, solubility management, and workflow-specific controls are critical for reproducibility.
1129 records 15/76 page Previous Next First page 上5页 1112131415 下5页 Last page